
Selecting Pharmacologic Interventions for #MASH 🔖 @DDS_Journal 🔑Patients w/diabetes, obesity & elevated cardiovascular disease risk may benefit from semaglutide 🔑Non-diabetic, non-obese may benefit from resmetirom (if semaglutide not tolerated) 👉link.springer.com/article/10…

























